SelectQuote (SLQT) Reports Strong Q4 Fiscal 2025 Results

By Tamara Parker • Thursday, August 21 15:38 • Permanent Link

SelectQuote, Inc. has reported its financial results for the fourth quarter of fiscal year 2025, showcasing significant growth and positive changes compared to the same period last year.

Consolidated revenue for the fourth quarter of fiscal year 2025 was $345.1 million, an increase from the $307.2 million reported for the fourth quarter of fiscal year 2024. The company also reported a consolidated net income of $12.9 million for the fourth quarter of fiscal year 2025, a stark contrast to the consolidated net loss of $31.0 million in the same period of fiscal year 2024.

The adjusted EBITDA for the fourth quarter of fiscal year 2025 was $2.7 million, down from the adjusted EBITDA of $14.4 million in the fourth quarter of fiscal year 2024.

In terms of segment highlights, the senior segment reported revenue of $82.5 million and adjusted EBITDA of $7.7 million. The healthcare services segment reported revenue of $214.0 million and adjusted EBITDA of $11.9 million, while the life segment reported revenue of $48.0 million and adjusted EBITDA of $6.9 million.

Looking ahead, SelectQuote, Inc. has provided guidance for fiscal year 2026, expecting revenue in the range of $1.650 billion to $1.750 billion and adjusted EBITDA in the range of $120 million to $150 million.

In the senior segment, there was a 28% decrease in revenue and a 72% decrease in adjusted EBITDA for the fourth quarter of fiscal year 2025 compared to the same period in fiscal year 2024.

SelectQuote, Inc. also saw a decrease in submitted policies for Medicare advantage, down 27% for the fourth quarter of fiscal year 2025 compared to the same period in fiscal year 2024.

For the healthcare services segment, there was a significant increase in revenue, up 47% for the fourth quarter of fiscal year 2025 compared to the same period in fiscal year 2024. The segment also experienced a substantial increase in adjusted EBITDA, up 1,204% for the same period.

The total number of SelectRX members increased by 31% as of June 30, 2025, compared to June 30, 2024, due to the company's strategy to grow SelectRX membership.

The life segment reported a 14% increase in revenue for the fourth quarter of fiscal year 2025 compared to the same period in fiscal year 2024. However, there was a 4% decrease in adjusted EBITDA for the same period.

As a result of these announcements, the company's shares have moved 43.17% on the market, and are now trading at a price of $2.62. For the full picture, make sure to review SelectQuote's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.